AprilBio Co.,Ltd.(397030)The company announced on the 2nd that it will participate in “BIO Europe 2026,” Europe’s largest biotech and pharmaceutical partnering event, to be held in Cologne, Germany, from the 9th to the 11th.
During the event, the company plans to meet with global pharmaceutical companies and biotech firms to introduce its new pipeline utilizing the REMAP platform. Based on this, it will explore potential collaborations, including technology transfers and joint development.
It also plans to pursue the acquisition of promising new drug candidates currently under development by external parties. The company’s strategy is to broaden its mid- to long-term business portfolio by securing external technologies in addition to developing its own pipeline and exporting technology.
AprilBio Co.,Ltd. stated, “This will be an important opportunity to assess the global commercialization potential of our new pipeline,” adding, “We will actively pursue strategic collaborations with global pharmaceutical companies and strengthen our technological competitiveness by acquiring external assets.”
Bio Europe, an event where pharmaceutical and biotech companies and investment institutions gather to discuss technology transfer, joint development, and strategic partnerships, is marking its 32nd edition this year.
